#ASH20: Loxo and Eli Lilly show off PhI/II data for their BTK inhibitor in mantle cell lymphoma

ASH is back and Loxo is primed and ready to present new data that they think will be quite exciting.

The Lilly-owned company is announcing results from a Phase I/II trial on its LOXO-305 program, and Saturday afternoon they detailed data in patients with mantle cell lymphoma (MCL) and other non-Hodgkin lymphomas. It’s the first of two expected presentations on the drug, as researchers are planning on releasing results from another patient population within the trial Monday.